The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectively As of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents ...

The FDA approved Rezdiffra to treat non-cirrhotic non-alcoholic steatohepatitis (NASH). Photo courtesy of U.S. Food and Drug Administration/Flickr 33,290 people played the daily Crossword recently ...

Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works. Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help ...

Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in the U.S.

Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works. Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help ...